Mid Europa Partners has agreed to sell CEE-focused consumer healthcare business Walmark to German pharmaceutical company STADA Arzneimittel.
The Czech Republic-based company manages a portfolio of brands with a direct presence in nine European countries. Walkmark’s products include a range of supplements for men women and children as well as digestion and joint health.
Under the deal, Walmark was valued at between $100m and $200m, a person with knowledge of the matter told AltAssets.
Mid Europa took over a 50 per cent stake in the business in December 2012, before going on to buy the remaining stake from the founding family in 2015.
Mid Europa co-managing partner Matthew Strassberg said, “The acquisition by STADA validates Walmark’s transformation from a family-led business to an international platform.
“Working in partnership with new management team, we have achieved our original vision for the Company and created a valuable strategic asset by developing and implementing a thorough approach to operational excellence and focused product innovation.”
Over the last 15 years, Mid Europa has invested more than €1bn in Czech Republic and Slovakia, in companies such as Karneval, CRa, and Alpha Medic.
Earlier this year, the firm announced the opening of its new office in Bucharest, Romania and promotion of one of its executives to an equity partner.
Mid Europa closed its fourth fund on €800m in 2016, alongside a co-investment facility of another €650m.
Copyright © 2019 AltAssets